ClinicalTrials.gg
CompletedNCT02848729Updated Feb 5, 2020Results posted

Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

A Phase 4 interventional study of Oral Acetaminophen and IV Acetaminophen in Pain, sponsored by Mallinckrodt. Completed at 3 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Mallinckrodt · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Feb 2016, registered Jul 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
94th of 137
50 · median 95
Started
2016
with 8 others
Phase 4
67 of 137
5 open now
Registered
93rd of 137
by date
Lead sponsor
6 of 137
Mallinckrodt

Among the 137 studies testing acetaminophen in Pain, this one is the 94th largest by enrollment, is one of 9 that started in 2016, is one of 67 in phase 4, and was the 93rd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

Morphine is the opioid used to treat pain after surgery. Acetaminophen (called APAP) can reduce the amount of opioids needed for this.

The problem is that morphine slows down digestion. That can delay pain relief from APAP pills. It can even change what the body does to the drug [pharmacokinetics (PK)].

Some doctors have started using intravenous (IV) APAP with morphine, instead of the pills.

This study will measure the PK of APAP pills and IV when used with morphine in healthy volunteers.

IV APAP will likely be more effective and cause fewer side effects when used with morphine to treat pain after surgery.

Read the detailed description

Acetaminophen can significantly reduce the use of opioid analgesics when both are used concomitantly for treating moderate to severe pain. The use of IV acetaminophen used concomitantly with opioids has increased in practice for postsurgical pain relief over orally administered acetaminophen because it provides an immediate peak plasma concentration and is believed to provide a faster analgesic effect. Opioids used to treat pain inhibit gastrointestinal motility, including delaying gastric emptying. In patients receiving opioids the absorption of orally administered acetaminophen may be delayed and could result in gastric accumulation of acetaminophen thereby markedly changing the pharmacokinetic profile. The opioid-induced inhibition of gastrointestinal motility would not be expected to affect IV acetaminophen pharmacokinetics. Thus coadministered IV acetaminophen with opioid would yield better outcome in efficacy and reduced risk of side effects comparing with coadministration of oral acetaminophen and opioids.

03

Conditions studied

  • Pain

Keywords

  • Post-surgical pain
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must have a health status of "healthy" assessed by the investigator and defined as no deviation from normal medical history, physical examination, vital signs, and clinical laboratory determinations.
  2. Subject must have a ≥ 19.0 and ≤ 32.0 kg/m² with a minimum weight of 110 pounds (50 kg) at Screening.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a positive test result for (HIV), (surface antigen), or virus antibody at screening.
  2. Subject has a history of any drug allergy, , or intolerance to acetaminophen or morphine/opioids or to any of the in the IV or oral formulations used.
  3. Subject has an oxygen saturation of less than 95% while awake at screening and check-in.
  4. Subject has a positive test result for drugs of abuse (minimum: opioids, barbiturates, cannabinoids, benzodiazepines, cocaine, amphetamine) or alcohol at the screening and check-in.
  5. Subject has donated or had significant loss of whole blood (480 mL or more) within 30 days, or plasma within 14 days prior to dosing.
  6. Subject has any other medical, psychiatric and/or social reason for exclusion as determined by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Treatment A: Oral Acetaminophen

    Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an IV infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of intravenous (IV) morphine (0.125 mg/kg) at Hours 0 and 6

    Drug: Oral Acetaminophen · Drug: IV Morphine · Drug: Saline

  • Experimental
    Treatment B: IV Acetaminophen

    Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.

    Drug: IV Acetaminophen · Drug: IV Morphine · Drug: Placebo Tablets

Interventions

  • Acetaminophen for oral administration (2 tablets, 500 mg/tablet)

    Also known as: APAP Oral

  • Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)

    Also known as: APAP IV

  • Morphine for IV administration (0.125 mg/kg)

  • DrugPlacebo Tablets

    Placebo tablets matching oral acetaminophen

  • DrugSaline

    Saline placebo matching IV acetaminophen

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve Over 6 Hours (AUC6) for Acetaminophen

    The area under the plasma drug concentration-time curve (AUC) is an estimate of how much drug remains available for the body to use, within a certain amount of time after the drug is administered. AUC6 is reported for each of the 6-hour dosing periods of acetaminophen before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration

    Time frame: hours -6 to 0, 0-6, 6-12, and 12-18 during treatment with each mode of acetaminophen administration

  2. Area Under the Plasma Concentration-time Curve Over 18 Hours (AUC18) for Acetaminophen After First Morphine Co-administration

    AUC18 is reported for the 18-hour treatment period after first morphine co-administration, for each route of acetaminophen administration

    Time frame: hours 0-18 during treatment with each mode of acetaminophen administration

  3. Maximum Concentration (Cmax) of Acetaminophen

    Following the administration of drugs, the plasma concentration generally reaches a single, well-defined peak which is the most drug that is available for the body to use (Cmax). Cmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12), and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.

    Time frame: hours -6 to 0, 0-6, 6-12, and 12-18 during treatment with each mode of acetaminophen administration

  4. Time to Maximum Concentration (Tmax) of Acetaminophen

    Following the administration of drugs, the time at which the plasma concentration reaches Cmax is called Tmax. Tmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.

    Time frame: hours -6 to 0, 0-6, 6-12 and 12-18 during treatment with each mode of acetaminophen administration

07

Results

Posted Jan 29, 2020

Participant flow

Participant flow — Overall Study
MilestoneOral AcetaminophenIV Acetaminophen
Started2723
Per protocol population1111
Safety population2723
Completed1112
Not completed1611
Withdrew: Withdrawal by subject10
Withdrew: Emesis1511

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve Over 6 Hours (AUC6) for Acetaminophen

The area under the plasma drug concentration-time curve (AUC) is an estimate of how much drug remains available for the body to use, within a certain amount of time after the drug is administered. AUC6 is reported for each of the 6-hour dosing periods of acetaminophen before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration

Time frame:
hours -6 to 0, 0-6, 6-12, and 12-18 during treatment with each mode of acetaminophen administration
Reported as:
Mean · hour*microgram per milliliter (h*mcg/mL)
Area Under the Plasma Concentration-time Curve Over 6 Hours (AUC6) for Acetaminophen
hour*microgram per milliliter (h*mcg/mL)First Dose - Before Morphine Co-administrationSecond Dose - During Morphine Co-administrationThird Dose - During Morphine Co-administrationFourth Dose - After Morphine Co-administration
Treatment A: Oral Acetaminophen31.00 ± 5.1128.51 ± 5.9625.31 ± 11.5952.38 ± 13.48
Treatment B: IV Acetaminophen42.56 ± 3.9444.37 ± 4.4643.59 ± 4.2149.05 ± 3.95
PrimaryArea Under the Plasma Concentration-time Curve Over 18 Hours (AUC18) for Acetaminophen After First Morphine Co-administration

AUC18 is reported for the 18-hour treatment period after first morphine co-administration, for each route of acetaminophen administration

Time frame:
hours 0-18 during treatment with each mode of acetaminophen administration
Reported as:
Mean · hour*microgram per milliliter (h*mcg/mL)
Area Under the Plasma Concentration-time Curve Over 18 Hours (AUC18) for Acetaminophen After First Morphine Co-administration
hour*microgram per milliliter (h*mcg/mL)After First Dose of Morphine Co-administration
Treatment A: Oral Acetaminophen82.50 ± 23.28
Treatment B: IV Acetaminophen63.58 ± 6.74
PrimaryMaximum Concentration (Cmax) of Acetaminophen

Following the administration of drugs, the plasma concentration generally reaches a single, well-defined peak which is the most drug that is available for the body to use (Cmax). Cmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12), and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.

Time frame:
hours -6 to 0, 0-6, 6-12, and 12-18 during treatment with each mode of acetaminophen administration
Reported as:
Mean · mcg/mL
Maximum Concentration (Cmax) of Acetaminophen
mcg/mLFirst Dose - Before Morphine Co-administrationSecond Dose - During Morphine Co-administrationThird Dose - During Morphine Co-administrationFourth Dose - After Morphine Co-administration
Treatment A: Oral Acetaminophen11.6 ± 4.117.29 ± 1.827.25 ± 3.9513.5 ± 3.31
Treatment B: IV Acetaminophen22.6 ± 3.8317.0 ± 1.4817.5 ± 1.9328.5 ± 4.31
PrimaryTime to Maximum Concentration (Tmax) of Acetaminophen

Following the administration of drugs, the time at which the plasma concentration reaches Cmax is called Tmax. Tmax is reported for the 6-hour dosing periods before (hours -6 to 0), during (hours 0-6 and 6-12) and after (hours 12-18) morphine co-administration for each route of acetaminophen administration.

Time frame:
hours -6 to 0, 0-6, 6-12 and 12-18 during treatment with each mode of acetaminophen administration
Reported as:
Mean · hours
Time to Maximum Concentration (Tmax) of Acetaminophen
hoursFirst Dose - Before Morphine Co-administrationSecond Dose - During Morphine Co-administrationThird Dose - During Morphine Co-administrationFourth Dose - After Morphine Co-administration
Oral Acetaminophen1.48 (0.75 to 2.02)1.64 (0.50 to 3.00)3.26 (0.50 to 5.85)2.84 (1.17 to 4.02)
IV Acetaminophen0.25 (0.25 to 0.27)0.50 (0.50 to 0.50)0.51 (0.50 to 0.57)0.25 (0.25 to 0.28)

Adverse events

Collected over From start of the study to the end of study (approximately 2 weeks, including wash-out period). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Acetaminophen0/27 (0%)0/27 (0%)22/27 (81.5%)
IV Acetaminophen0/23 (0%)0/23 (0%)17/23 (73.9%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventOral AcetaminophenIV Acetaminophen
VomitingGastrointestinal disorders15/2711/23
NauseaGastrointestinal disorders12/2710/23
DizzinessNervous system disorders4/274/23
SomnolenceNervous system disorders4/271/23
Euphoric moodPsychiatric disorders1/273/23
HeadacheNervous system disorders2/272/23
ParaesthesiaNervous system disorders1/272/23
PruritusSkin and subcutaneous tissue disorders2/272/23
AstheniaGeneral disorders2/270/23
Catheter site painGeneral disorders2/270/23

Baseline characteristics

All participants with emesis were removed from the study, with no replacement. Because 7 of 9 females had emesis at the first dose, an amendment was written to exclude females. Therefore, demographics are provided for the per protocol population.

Age, Continuous
Age, Continuous(years)Oral AcetaminophenIV AcetaminophenTotal
Mean33.1 ± 9.8232.5 ± 11.2532.8 ± 10.31
Sex: Female, Male
Sex: Female, Male(Participants)Oral AcetaminophenIV AcetaminophenTotal
Female011
Male111021
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Oral AcetaminophenIV AcetaminophenTotal
White7916
Black or African American224
Hispanic or Latino Ethnicity4610
Not Hispanic or Latino7512
08

Study locations

3 sites
  • University of Arizona College of Pharmacy
    Tucson, Arizona 85718, United States
  • NEMA Research, Inc.
    Naples, Florida 34108, United States
  • The University of Rhode Island College of Pharmacy
    Kingston, Rhode Island 02881, United States
09

References and documents

Publications

  • Raffa RB, Pawasauskas J, Pergolizzi JV Jr, Lu L, Chen Y, Wu S, Jarrett B, Fain R, Hill L, Devarakonda K. Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects. Clin Drug Investig. 2018 Mar;38(3):259-268. doi: 10.1007/s40261-017-0610-4. PubMed 29214506 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Mar 2016, 1 month.

Results were first posted in Jan 2020, 3 years 10 months after primary completion.

Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2016
First posted
Jul 28, 2016
StartActual
Feb 2016
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Results first posted
Jan 29, 2020
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02848729
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Jul 28, 2016
Start date
Feb 2016
Primary completion
Mar 2016
Completion
Mar 2016
Results posted
Jan 29, 2020
Last update
Feb 5, 2020

Study contacts

Global Clinical Leader
study director · Mallinckrodt

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Morphine

Start the discussion